GlassScriptPhysician profile
Brian C Taylor
NPI 1043846017
$12,440.91
in general payments reported to CMS, 2019-2025
32 companies · $2,955 in 2025
The $2,955 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,393 · 2022: $1,999 · 2023: $2,565 · 2024: $2,529 · 2025: $2,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,851 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,850.78 |
| Education | $198.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,750.20 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,593.35 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $1,432.60 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $1,133.64 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $1,108.35 | 2021-2025 | Rexulti, Brintellix |
| Alkermes, INC. | $1,069.58 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $694.00 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $620.65 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $372.48 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $351.99 | 2021-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $333.24 | 2022-2024 | Jornay Pm |
| Corium, LLC | $306.53 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $275.34 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $274.94 | 2022-2025 | Invega Sustenna, Spravato |
| Tris Pharma INC | $153.74 | 2022-2025 | Dyanavel Xr |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $122.82 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $115.68 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $108.28 | 2025 | Jornay Pm |
| Eisai INC. | $92.85 | 2021-2022 | |
| Indivior INC. | $81.85 | 2021-2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $75.23 | 2022-2023 | Quviviq |
| Neuronetics, INC. | $69.02 | 2023 | Neurostar Tms Therapy System |
| Sage Therapeutics, LLC | $61.67 | 2024-2025 | Zurzuvae |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.53 | 2022 | |
| Alfasigma USA, INC. | $40.15 | 2021-2022 | |
| Almatica Pharma LLC | $38.29 | 2021-2022 | |
| Tempus Ai, INC | $29.42 | 2024 | |
| Harmony Biosciences LLC | $26.29 | 2023 | Wakix |
| Azurity Pharmaceuticals, INC. | $20.49 | 2024 | Horizant |
| Avanir Pharmaceuticals, INC. | $18.01 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.83 | 2021 | |
| Merck Sharp & Dohme LLC | $13.87 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.